Dehydroepiandrosterone
From DrugPedia: A Wikipedia for Drug discovery
(Difference between revisions)
| Line 74: | Line 74: | ||
|- | |- | ||
|} | |} | ||
| - | + | {| border="1;width:100%; height:200px;style=text-align:center" | |
| - | Organism | + | |+'''Toxicity:''' |
| + | |- | ||
| + | ! style="background:brown; color:white" |Organism | ||
| + | ! style="background:brown; color:white" |Test Type | ||
| + | ! style="background:brown; color:white" |Route | ||
| + | ! style="background:brown; color:white" |Reported Dose (Normalized Dose) | ||
| + | ! style="background:brown; color:white" |Effect | ||
| + | ! style="background:brown; color:white" |Source | ||
| + | |- | ||
|man | |man | ||
|TDLo | |TDLo | ||
Revision as of 05:07, 31 October 2008
Dehydroepiandrosterone
Pubchem(5881)
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
Negative modulator of GABAA receptors.
Drug Type: Small Molecule; Experimental
KEGG Pathway(C01227) Androgen and estrogen metabolism Prostate cancer
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 15983 | 1E3R | Ha NC, Kim MS, Lee W, Choi KY, Oh BHDetection of large pKa perturbations of an inhibitor and a catalytic group at an enzyme active site, a mechanistic basis for catalytic power of many enzymesJ. Biol. Chem. v275, p.41100-41106 |
| 55806 | 1COY | Li J, Vrielink A, Brick P, Blow DMCrystal structure of cholesterol oxidase complexed with a steroid substrate: implications for flavin adenine dinucleotide dependent alcohol oxidasesBiochemistry v32, p.11507-11515 |
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 140-141 | deg C | EXP | |
| log P (octanol-water) | 3.23 | (none) | EXP | |
| Water Solubility | 63.5 | mg/L | 25 | EXP |
| Vapor Pressure | 2.23E-08 | mm Hg | 25 | EST |
| Henry's Law Constant | 6.62E-09 | atm-m3/mole | 25 | EST |
| Atmospheric OH Rate Constant | 1.27E-10 | cm3/molecule-sec | 25 | EST |
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 10mg/kg/2W-I (10mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Annals of Internal Medicine. Vol. 129, Pg. 588, 1998. |
| mouse | LD50 | oral | > 10gm/kg (10000mg/kg) | British UK Patent Application. Vol. #2208473, | |
| mouse | LD50 | subcutaneous | 900mg/kg (900mg/kg) | British UK Patent Application. Vol. #2208473, | |
| rat | LD50 | oral | > 10gm/kg (10000mg/kg) | British UK Patent Application. Vol. #2208473, | |
| rat | LD50 | subcutaneous | 1gm/kg (1000mg/kg) | British UK Patent Ap |
